EK - Local recommendations (Genito-urinary)
Use documents past their review date with caution
Urinary frequency, enuresis and incontinence
| Recommendation | Approval date | Review date |
| EKPG Recommendation - Botulinum toxin type A for overactive bladder with symptoms of urinary incontinence, urgency and frequency - PR 2014-10 | October 2014 | April 2021 |
| EKPG Recommendation - Botulinum toxin type A for urinary incontinence due to neurogenic detrusor overactivity PR2014-09 | September 2014 | April 2021 |
| Primary Care Management of Overactive Bladder (OAB) In Women | October 2023 | October 2025 |
Urinary retention
| Recommendation | Approval date | Review date |
| Tadalafil use in Benign Prostatic Hyperplasia EKPG | October 2013 | April 2021 |
Contraception-hormonal
| Recommendation | Approval date | Review date |
| Recommendations for the Use oral contraceptives | April 2013 | April 2021 |
| EKPG recommendation - Zoely | February 2014 | April 2021 |
| EKPG recommendation - Sayana | February 2014 | April 2021 |
| Qlaira recommendation EKPG | July 2013 | April 2021 |
| EKPG recommendation - Drospirenone (Yasmin) COC | October 2014 | April 2021 |
| EKPG recommendation - Levonelle | February 2014 | April 2021 |
Erectile dysfunction
| Recommendation | Approval date | Review date |
| EKPG recommendation - Alprostadil Cream | October 2014 | April 2021 |
| Dapoxetine Recommendation | April 2015 | April 2021 |
General (Genito-urinary)
| Recommendation | Approval date | Review date |
| Esmya medicines safety update | February 2018 | February 2021 |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary